Board Meeting Details

The Board of Directors meeting was held on 10th August, 2026, commencing at 1:10 p.m. and concluding at 3:05 p.m. The meeting approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026.

Standalone Financial Results (₹ in Crore, except per share data)

Quarter Ended 30/06/2026 (Unaudited)

  • Revenue from operations: ₹561
  • Other income: ₹33
  • Total income: ₹594
  • Total expenses: ₹487
  • Cost of materials consumed: ₹106
  • Purchase of stock-in-trade: ₹57
  • Changes in inventories: ₹0.08
  • Employee benefits expense: ₹85
  • Finance costs: ₹41
  • Depreciation and amortization: ₹41
  • Other expenses: ₹155
  • Profit before exceptional items and tax: ₹107
  • Exceptional items: None
  • Profit before tax: ₹107
  • Tax expense: ₹0
  • Net Profit after tax: ₹107
  • Other Comprehensive Income (net of tax): ₹0.08
  • Total Comprehensive Income: ₹107
  • Paid-up equity share capital (face value ₹5 each): ₹81
  • Earnings per share (face value ₹5 each): Not explicitly stated in standalone table

Comparative Standalone Figures

  • Quarter Ended 31/03/2026 (Audited): Total income ₹571, Net Profit after tax ₹167
  • Quarter Ended 30/06/2025 (Unaudited): Total income ₹438, Net Profit after tax ₹69
  • Year Ended 31/03/2026 (Audited): Figures not provided in standalone table

Consolidated Financial Results (₹ in Crore, except per share data)

Quarter Ended 30/06/2026 (Unaudited)

  • Revenue from operations: ₹960
  • Other income: ₹0
  • Total income: ₹960
  • Total expenses: ₹844
  • Cost of materials consumed: ₹191
  • Purchase of stock-in-trade: ₹127
  • Changes in inventories: ₹(22) [negative]
  • Employee benefits expense: ₹203
  • Finance costs: ₹52
  • Depreciation and amortization: ₹55
  • Exchange fluctuation loss, net: ₹(4) [negative]
  • Other expenses: ₹218
  • Profit before exceptional items and tax: ₹116
  • Exceptional items: None
  • Profit before tax: ₹116
  • Tax expense: ₹9 (Current tax: ₹7, Deferred tax: ₹2)
  • Net Profit after tax: ₹107
  • Attributable to equity shareholders: ₹106
  • Attributable to non-controlling interest: ₹1
  • Other Comprehensive Income (net of tax): ₹14
  • Total Comprehensive Income: ₹121
  • Attributable to equity shareholders: ₹116
  • Attributable to non-controlling interest: ₹5
  • Paid-up equity share capital (face value ₹5 each): ₹81
  • Earnings per share - Basic: ₹6.55* (not annualized)

Comparative Consolidated Figures

  • Quarter Ended 31/03/2026: Total income ₹1,010, Net Profit after tax ₹164
  • Quarter Ended 30/06/2025: Total income ₹758, Net Loss after tax ₹(108)
  • Year Ended 31/03/2026: Total income ₹3,484, Net Profit after tax ₹199

Audit and Review Details

The financial results were subjected to limited review by the statutory auditors, MSKC & Associates LLP. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 issued by ICAI.

The auditors issued an unmodified review conclusion stating that nothing has come to their attention that causes them to believe that the financial results contain any material misstatement.

Subsidiary Information

The consolidated results include 28 subsidiaries. Key subsidiary information:

  • 5 subsidiaries were reviewed by other auditors with total revenues of ₹777 crores and total net loss of ₹2 crores
  • 18 subsidiaries were not reviewed by their auditors, with total revenue of ₹46 crores and total net profit of ₹10 crores
  • Complete list of 28 subsidiaries provided in annexure

Business Segment Information

The Company and Group are exclusively into the Pharmaceutical business segment.

Additional Information

  • Figures for the quarter ended March 31, 2026 are balancing figures between audited annual figures and reviewed quarterly figures
  • The results have been filed with BSE Limited and National Stock Exchange of India Limited